Users Online: 92 | Home Print this page Email this page
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 

    Article Cited by others


A comprehensive study on regulatory requirements for development and filing of generic drugs globally

Handoo Shweta, Arora Vandana, Khera Deepak, Nandi Prafulla Kumar, Sahu Susanta Kumar

Year : 2012| Volume: 2| Issue : 3 | Page no: 99-105

   This article has been cited by
1 International Comparison of Five Herbal Medicine Registration Systems to Inform Regulation Development: UnitedKingdom, Germany, UnitedStates ofAmerica, United Arab Emirates and Kingdom of Bahrain
Azhar H. Alostad,Douglas T. Steinke,Ellen I. Schafheutle
Pharmaceutical Medicine. 2018;
[Pubmed]  [Google Scholar] [DOI]
2 The Impact of Patent Expiry on Drug Prices: A Systematic Literature Review
Gerard T. Vondeling,Qi Cao,Maarten J. Postma,Mark H. Rozenbaum
Applied Health Economics and Health Policy. 2018;
[Pubmed]  [Google Scholar] [DOI]
3 Status and trends in the development of clinical diagnostic agents
Tatjana Opacic,Vera Paefgen,Twan Lammers,Fabian Kiessling
Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology. 2016;
[Pubmed]  [Google Scholar] [DOI]
4 BCS Biowaivers: Similarities and Differences Among EMA, FDA, and WHO Requirements
Barbara M. Davit,Isadore Kanfer,Yu Chung Tsang,Jean-Michel Cardot
The AAPS Journal. 2016;
[Pubmed]  [Google Scholar] [DOI]
5 Generic medicines: issues and relevance for global health
Proteesh Rana,Vandana Roy
Fundamental & Clinical Pharmacology. 2015; 29(6): 529
[Pubmed]  [Google Scholar] [DOI]
6 USA FDAs implementation of QbD and GDUFA: A wakeup call for other regulatory agencies across the globe
Manisha Saini,Swagat Tripathy,Harish Dureja
Journal of Medical Marketing. 2014; 14(2-3): 108
[Pubmed]  [Google Scholar] [DOI]


Read this article